Zidovudine + Didanosine

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

AIDS Dementia Complex

Conditions

AIDS Dementia Complex, HIV Infections

Trial Timeline

— → Sep 1, 1992

NCT ID

NCT00000657

About Zidovudine + Didanosine

Zidovudine + Didanosine is a phase 2 stage product being developed by Bristol Myers Squibb for AIDS Dementia Complex. The current trial status is completed. This product is registered under clinical trial identifier NCT00000657. Target conditions include AIDS Dementia Complex, HIV Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00001025	Phase 2	Completed	—	May 1, 1995	HIV Infections
NCT00000671	Phase 2	Completed	—	—	HIV Infections
NCT00000979	Phase 2	Completed	—	—	HIV Infections
NCT00001024	Pre-clinical	Completed	—	Jun 1, 2002	HIV Infections
NCT00000637	Phase 3	Completed	—	Sep 1, 1996	HIV Infections
NCT00000657	Phase 2	Completed	—	Sep 1, 1992	AIDS Dementia Complex
NCT00000656	Phase 1	Completed	—	Nov 1, 1993	HIV Infections
NCT00002035	Pre-clinical	Completed	—	Apr 1, 1992	HIV Infections
NCT00000823	Phase 2	Completed	—	Feb 1, 2000	HIV Infections

Competing Products

20 competing products in AIDS Dementia Complex

See all competitors

Product	Company	Stage	Hype Score
Esomeprazole	AstraZeneca	Phase 3	77
Esomeprazole	AstraZeneca	Phase 3	77
Selumetinib	AstraZeneca	Phase 1/2	41
Metformin	Merck	Phase 2/3	65
Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) + Comparator: placebo	Merck	Phase 2	52
Recombinant Human Papillomavirus Nonavalent Vaccine	Merck	Phase 3	77
rituximab + CHOP	Roche	Phase 2	52
R-EPOCH and cART	Roche	Phase 2	52
Elvitegravir, Cobicistat, TAF, FTC + Efavirenz, TDF, and 3TC	Gilead Sciences	Pre-clinical	22
Switch to E/C/FTC/TAF daily	Gilead Sciences	Phase 1/2	40
Biktarvy + Symtuza	Gilead Sciences	Phase 3	76
Truvada	Gilead Sciences	Approved	84
ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOS	Gilead Sciences	Phase 2/3	64
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)	Gilead Sciences	Approved	84
ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral Tablet	Gilead Sciences	Phase 2	51
E/C/F/TAF + E/C/F/TAF (Low Dose)	Gilead Sciences	Phase 2/3	64
EVG + Background regimen	Gilead Sciences	Phase 2/3	64
Emtricitabine and Tenofovir	Gilead Sciences	Approved	84
TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tablets	Gilead Sciences	Phase 3	76
Maraviroc	Pfizer	Phase 1	32

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved